Clearside Biomedical to Report Second Quarter 2023 Financial Results and Provide Corporate Update on Monday, August 14, 2023
01 août 2023 07h05 HE
|
Clearside Biomedical, Inc.
ALPHARETTA, Ga., Aug. 01, 2023 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the...
Clearside Biomedical Highlights Excellent Safety Profile of CLS-AX and Potential for Extended Duration of Effect in Data Presentation at the American Society of Retina Specialists 41st Annual Scientific Meeting
31 juil. 2023 07h05 HE
|
Clearside Biomedical, Inc.
- Suprachoroidal Injection of CLS-AX Resulted in Favorable Safety Data, Durability and Biologic Effect Over 6 Months - ALPHARETTA, Ga., July 31, 2023 (GLOBE NEWSWIRE) -- Clearside Biomedical,...
Clearside Biomedical’s Suprachoroidal Injection Platform to be Featured at Upcoming ASRS and OIS Scientific Meetings
20 juil. 2023 07h05 HE
|
Clearside Biomedical, Inc.
ALPHARETTA, Ga., July 20, 2023 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the...
Clearside Biomedical Announces Enrollment of Multiple Participants in its ODYSSEY Phase 2b Clinical Trial of CLS-AX (axitinib injectable suspension) in Wet AMD
17 juil. 2023 07h05 HE
|
Clearside Biomedical, Inc.
- Evaluating CLS-AX as a Potential Twice-a-Year Therapy - - Trial Progressing with Topline Results Expected in Q3 2024 - ALPHARETTA, Ga., July 17, 2023 (GLOBE NEWSWIRE) -- Clearside Biomedical,...
Clearside Biomedical CEO George Lasezkay to Present at the SHARE™️ Series Investor Event on Monday, July 17, 2023
11 juil. 2023 16h05 HE
|
Clearside Biomedical, Inc.
ALPHARETTA, Ga., July 11, 2023 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the...
Clearside Biomedical Asia-Pacific Partner Arctic Vision Announces the Acceptance in Australia of its New Drug Application for Suprachoroidal Use of Arcatus® for the Treatment of Uveitic Macular Edema
10 juil. 2023 07h05 HE
|
Clearside Biomedical, Inc.
- XIPERE® is referred to as Arcatus (ARVN001) by Arctic Vision – ALPHARETTA, Ga., July 10, 2023 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company...
Clearside Biomedical Opens Enrollment in ODYSSEY Phase 2b Clinical Trial of CLS-AX (axitinib injectable suspension) in Wet AMD
01 juin 2023 07h05 HE
|
Clearside Biomedical, Inc.
- U.S. Clinical Sites Screening Treatment-Experienced Participants with Wet AMD - - ODYSSEY Topline Results Expected in Q3 2024 - ALPHARETTA, Ga., June 01, 2023 (GLOBE NEWSWIRE) --...
Clearside Biomedical Announces First Quarter 2023 Financial Results and Provides Corporate Update
11 mai 2023 07h05 HE
|
Clearside Biomedical, Inc.
- Phase 2b ODYSSEY Trial of CLS-AX in Wet AMD Expected to Open Enrollment in Q2 2023 - - Positive Safety Data, Duration and Biologic Effect of CLS-AX Over 6 Months in OASIS Phase 1/2a Extension...
Clearside Biomedical to Participate in a Fireside Chat at the JMP Securities Life Sciences Conference
09 mai 2023 16h30 HE
|
Clearside Biomedical, Inc.
ALPHARETTA, Ga., May 09, 2023 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the...
Clearside Biomedical to Report First Quarter 2023 Financial Results and Provide Corporate Update on Thursday, May 11, 2023
02 mai 2023 07h05 HE
|
Clearside Biomedical, Inc.
ALPHARETTA, Ga., May 02, 2023 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the...